Abstract library

46 results for "Panova".
#2742 Anti-Tumor Effects of Semaphorin 4D Blockade Unravel a Novel Pro-Invasive Mechanism of Vascular Targeting Agents
Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PhD Oriol Casanovas
#2867 Experience of Treatment with Everolimus in Patients with Well-Differentiated Neuroendocrine Tumors (NET) of Various Localizations at the NN Blokhin NMRCO, Moscow, Russia
Introduction: Everolimus (EVE) (mTOR inhibitor) is an effective drug in the treatment of well-differentiated NETs of different localizations, however, prognostic factors for the correct choice of therapy are not well understood.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Anna Kuznetsova
#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova
#2880 177-Lu-DOTATATE in 200 Patients with Neuroendocrine Tumors: Real-World Data from the SEPTRALU Registry
Introduction: Patients with neuroendocrine tumors have few treatment options after progression to first-line somatostatin analogues.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Alberto Carmona-Bayonas
#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study
Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Mercedes Mitjavila Casanovas
#2958 The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction: Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
#91 Endoscopic ultrasound of 66 insulinomas
Introduction: Ultrasound is the virtual representation of the morphology of organs and tissues. Endoscopic ultrasound can be used in detailed scanning of pancreas and preoperative topical diagnostics of insulinomas. Insulinoma requires surgical treatment in all cases. This fact allows control of preoperative diagnostic methods.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Tatiana L. Silina
#185 Czech Neuroendocrine Registry - First Results
Introduction: The Czech Neuroendocrine Registry was started in October 2009 as a platform that should facilitate the data based on communication among various specialists treating NETs.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Jaroslava Barkmanova
#389 Czech Neuroendocrine Tumor Registry - 28 Months Results
Introduction: Cooperative Group for NET was established on 22 April 2008. It continues with the practices of the Czech Carcinoid Group since 1998. The real incidence of neuroendocrine tumors is unknown. The majority remain undiagnosed. Therefore, the Czech Registry started in October 2009 to identify NET patients and to facilitate the diagnosis and therapy in centers with NET experts.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Jaroslava Barkmanova
#403 Insulinomas in Children
Introduction: Insulinomas are extremely rare tumors in children and an uncommon first manifestation of MEN1 syndrome. Insulinomas are usually benign tumors with only a few reports of malignant cases in children.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: MD Maria Melikian
Keywords: MEN-1